Home › Research › Topics › gut
gut
173 studies tagged gut, dated 1998-01-01 to 2026-10-23. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Evidence that the perinatal maternal microbiome mediates metabolite signaling programs that drive sex-specific microglial metabolic alterations and Alzheimer’s disease susceptibility 2026-10-23
- Change in gut microbiome precedes symptomatic Alzheimer’s disease and is correlated with amyloid-beta accumulation in the brain 2026-10-19
- The microbial soy metabolite S-equol mitigates cadmium neurotoxicity in mice 2026-10-06
Studies
173 studies carry this tag.
Date range
1998 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 13
- Scientific reports 8
- Molecular neurobiology 5
- bioRxiv 5
- Aging 4
104 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Maternal microbiome-dependent programming of neuroimmune and metabolic pathways during early development may critically shape sex-specific susceptibility to Alzheimer’s disease (AD) later in life.
-
Early Ap accumulation is associated with distinct gut microbial signatures and reduced neuroactive metabolic potential, identifying targets for potential preclinical AD intervention.
-
Environmental exposures are major but understudied determinants of chronic disease.
-
Alzheimer’s disease is a progressive, currently irreversible, neurodegenerative disorder associated with the accumulation of β-Amyloid (Aβ) plaques between cells and tau (τ) tangles within cells.
-
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized primarily by progressive cognitive impairment.
-
These findings identify TTR as a contributor of adaptive neurovascular homeostasis during gut-derived neuroinflammation.
-
16/100
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder influenced by genetic, environmental, and lifestyle factors.
-
Gut microbiome differences in Alzheimer’s disease (AD) are typically cataloged taxon by taxon, yet bacterial competition and cross-feeding make species’ roles dependent on the entire community.
-
Gut microbial metabolites serve as functional mediators of gut–brain communication, linking microbial alterations to neurodegenerative pathology.
-
Our findings provide evidence that age-related changes in the gut microbiota, particularly reductions in Bifidobacterium , partially mediate cognitive decline in older adults.
-
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlations to the validation of causal relationships.
-
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β plaques, neurofibrillary tau tangles, neuroinflammation, and progressive cognitive decline.
-
DMII provides a metabolomics-based framework for assessing diet-related chronic inflammation using metabolomics data.
-
Alzheimer's disease (AD) is incurable and increasingly attributed to gene-environment interactions.
-
Alzheimer's disease (AD), the leading cause of dementia worldwide, imposes a growing clinical and societal burden, yet no therapies have been proven to alter its progression despite decades of intensive research.
-
16/100
Structured Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of developing Alzheimer’s disease (AD).
-
Alzheimer's disease (AD) is projected to become the highest-burden neurological disorder globally.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options, underscoring the need for novel therapeutic targets.
-
The gut-brain axis plays a critical role in maintaining neuronal integrity and influencing the progression of Alzheimer's disease (AD).
-
43/100
Microbiota residing in the human gastrointestinal tract play a critical role in maintaining homeostasis through immune regulation, metabolic activity, and signaling to the central nervous system.
-
Nutritional supplementation is emerging as a promising strategy to support clinical management of early Alzheimer's disease (AD), partly through modulation of the intestinal microbiome via the microbiota-gut-brain axis.
-
Seventy-four participants completed the study.
-
Previous studies in humans and humanized APOE mice have demonstrated APOE-genotype-specific differences in the GMB.
-
pAD patients showed intestinal inflammation, an altered GM profile, blood changes in the tryptophan metabolism, and reduced glutamate levels compared with HC (p-value < 0.049).
-
The gut-brain axis explains that changes in the intestinal microbiota influence Alzheimer's disease (AD).
-
66/100
Emerging evidence suggests a potential role of gut dysbiosis in neurodegenerative disorders and, in particular, Alzheimer's disease (AD) pathology and cognitive decline.
-
Alzheimer's disease (AD) is increasingly recognized as a condition shaped not only by central nervous system pathology but also by complex, bidirectional interactions between the gut, brain, and immune system.
-
We identified 59 key microbial species linked to MCI and AD biomarkers.
-
The hallmarks of Alzheimer's disease (AD) include brain dysfunction and the buildup of amyloid and tau proteins.
-
Alzheimer's disease (AD) is a progressive, degenerative disorder of the central nervous system.
-
Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches for its prevention and therapy are critically needed.
-
Despite recent advances, severe acute pancreatitis (SAP) remains a lethal inflammation with limited treatment options.
-
The gut microbiota plays a crucial role in the pathogenesis of AD through continuous bidirectional communication via the microbiota-gut-brain axis.
-
Psen1 expression was regulated in experimental gut inflammation and in patients with IBD.
-
Arteriosclerotic cerebral small vessel disease (aCSVD) is a major cause of stroke and dementia.
-
43/100
The gastrointestinal (GI) tract, home to the largest microbial population in the human body, plays a crucial role in overall health through various mechanisms.
-
Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated.
-
An essential regulator of neurodegenerative conditions like Alzheimer's disease (AD) is the gut microbiota.
-
Regulating the gut flora ecological balance upregulates neurotrophic factor expression, regulates the microbiota-gut-brain (MGB) axis, and suppresses the inflammatory responses.
-
45/100
Alzheimer's disease (AD) is a fatal progressive neurodegenerative disease.
-
There were 20 positive and 16 negative causal effects between genetic liability in the gut microbiota and dementia.
-
Alzheimer's disease (AD) is the most prevalent type of dementia, but its etiopathogenesis is not yet fully understood.
-
JOURNAL/nrgr/04.03/01300535-202410000-00029/figure1/v/2024-02-06T055622Z/r/image-tiff Disturbances in the microbiota-gut-brain axis may contribute to the development of Alzheimer's disease.
-
Disturbances in the local and peripheral immune systems are closely linked to a wide range of diseases.
-
47/100
Alzheimer's disease is a complex neurodegenerative disorder leading to a decline in cognitive function and mental health.
-
45/100
Alzheimer's disease (AD) is characterized by amyloid-β accumulation in the brain and hyperphosphorylated tau aggregation, as well as neuroinflammation.
-
The advent of high-throughput 'omics' technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer's disease (AD), a neurodegenerative disorder.
-
In the last decade, the role of the microbiota-gut-brain axis has been gaining momentum in the context of many neurodegenerative and metabolic disorders, including Alzheimer's disease (AD) and diabetes, respectively.
-
The evolution of the understanding of the intestinal microbiota and its influence on our organism leverages it as a potential protagonist in therapies aimed at diseases that affect not only the intestine but also neural pathways and the central nervous system itself.
-
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment.
From across this tag
7 of the 173 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease
- Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain
- Microbiome-Derived Lipopolysaccharide Enriched in the Perinuclear Region of Alzheimer’s Disease Brain
- Nutrition, Gut Microbiota, and Alzheimer's Disease
- Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms
- Gut Microbiota is Altered in Patients with Alzheimer's Disease
- The Gut Microbiome and Alzheimer's Disease: A Growing Relationship